In the last 20 years, improvements in metastatic colorectal cancer treatment lead to a radical raise of outcomes with median survival reaching now more than 30 months. Despite that, the identification of predictive and/or prognostic biomarker still represents a challenging issue, and until today, although clinician and researchers might face with a deeper knowledge of biological mechanisms related to colorectal cancer, many pieces of evidence underline the heterogeneity and the dynamism of such disease. In the present review, we describe the road leading to the discovery of RAS mutations, BRAF V600E mutation, and microsatellite instability role in colorectal cancer; second, we discuss some of the possible major pitfalls of biomarker research, and lastly, we give new suggestions for future research in this field.
C olorectal cancer (CRC) is the second highest cause of cancer mortality both in the United States and in Europe. Approximately 25% of cases present with metastases at the time of diagnosis, whereas another 25% of patients will develop metastases during the course of the disease. 1, 2 The median overall survival (OS) of metastatic CRC (mCRC) patients in the last 20 years has remarkably improved from approximately 6 to 12 months 3 to more than 30 months in the last presented first-line clinical trials. [4] [5] [6] [7] Such results derive from the development of new intensive and/or tailored therapies, which incorporate cytotoxic drugs and targeted therapies such as the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, cetuximab and panitumumab, and the antiangiogenic bevacizumab, [8] [9] [10] the integration of medical treatments with more and more effective locoregional and surgical approaches, 11 and from a deeper knowledge of CRC biology. 12 Moreover, steps forward have been done, thank to the approval of new drugs, such as aflibercept, 13 regorafenib, 14 TAS 102,  15 and ramucirumab. 16 Despite those improvements, the identification of the most effective treatment for an individual patient is still mainly based on clinical considerations such as symptoms, performance status, extent of disease, patients' preferences, and treatment history, whereas the identification of predictive and/or prognostic biomarkers able to guide treatment decision stands as a challenging issue in the management of CRC patients. According to the National Institutes of Health biomarker definition working group, a biological marker (biomarker) is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. 17 A prognostic marker influences patients' outcome regardless of treatment, whereas a predictive biomarker identifies patients more likely to benefit from a specific treatment. Personalizing treatment according to biomarkers might have important clinical utility and public health significance, leading to improved therapeutic outcome through a reduction of harm and/or costs associated with treatments.
In the first part of the review, we will summarize the role and the discovery history of the RAS, BRAF, and microsatellite instability (MSI), which represent at the moment the only validated biomarker in CRC. In the second part, we focus on possible reasons of biomarker discovery failure, and we propose our way-out strategies to make translational research in this field more effective.
RAS: THE NEVER ENDING STORY
Cetuximab and panitumumab received the Food and Drug Administration approval in 2004 and 2006, respectively, after the demonstration of efficacy in randomized trials for mCRC patients in advanced lines of treatments. In comparison with best supportive care (BSC), cetuximab was associated with a significant improvement in OS (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.64-0.92; P = 0.005) and in progression-free survival (PFS) (HR, 0.68; 95% CI, 0.57-0.80; P < 0.001) 18 ; similarly, panitumumab demonstrated an improvement of PFS compared with BSC (HR, 0.54; 95% CI, 0.44-0.66; P < 0.0001). No difference was observed in terms of OS (HR, 1.00; 95% CI, 0.82-1.22), but 76% of BSC patients received panitumumab in the crossover study. 19 Interestingly, looking at PFS curves, a clear subgroup effect was hypothesized: it seemed that more than 50% of patients in the experimental arm did not derive any advantage from either cetuximab or panitumumab. Moving from such consideration, the search for predictive markers of response or resistance to anti-EGFRs started.
Epidermal growth factor receptor expression tested by immunohistochemistry (IHC) on surgical specimens was the first proposed predictive factor of response to anti-EGFRs. 20, 21 However, some authors described clinical responses to cetuximab in EGFR-negative tumors. 22, 23 Technical issues such as tissue fixation, storage time, 24 nonhomogeneous pattern of expression, personal interpretation of results, and biological limitations such as lack of concordance between primaries and related metastases 25 have been proposed as possible limitations of the adoption of EGFR expression measured by means of IHC as a predictive factor of anti-EGFR activity. Similarly, because of reproducibility issues and high costs, EGFR amplification detected by fluorescent in situ hybridization was not deemed as a reliable biomarker. [26] [27] [28] [29] The revolution came from the discovery of KRAS exon 2 (codons 12 and 13) mutations as negative predictive factor of response to anti-EGFRs. KRAS is a GTPase protein involved in signal transduction, cellular growth, differentiation, proliferation, and survival and is encoded by RAS family member genes. 30, 31 Mutations of RAS lead to a defective GTPase activity that causes a hyperactivation of the signaling cascade 32 determining an uncontrolled activity of the downstream effectors, such as RAF proteins and MAP kinases. KRAS mutations are found in approximately 40% to 50% of mCRC patients and more frequently affect exon 2. 33, 34 First evidence of the role of KRAS exon 2 mutation was obtained in small retrospective series 29 and was confirmed in post hoc analyses of phase III randomized trial, both in advanced setting 18, 35, 36 and in first-line 37, 38 and subsequently in metaanalyses. 39, 40 In 2008, Food and Drug Administration and EMA restricted the use of anti-EGFRs to KRAS exon 2 wild-type patients; however, it seemed that only a small percentage of wildtype patients derived benefit from those drugs, and researchers pursued the effort of refining patient selection to anti-EGFRs.
Additional rare RAS activating mutations, involving exon 3 (codons 59 and 61) and exon 4 (codons 117 and 146) of KRAS and exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 of NRAS (codons 117 and 146), were deemed as possible additional negative predictive factors. Preliminary evidence came from a retrospective series of 87 KRAS exon 2 wild-type mCRC patients treated with irinotecan and cetuximab. KRAS codons 61 and 146 mutant patients showed a lower response rate (0% vs. 37%; P = 0.047) and worse PFS (HR, 0.45; P = 0.023) compared with wild-type patients. 41 Moreover, in a large data set of chemorefractory mCRC patients (N = 733) treated with cetuximab and chemotherapy in 7 European countries, it was shown that, among KRAS wild-type patients, carriers of NRAS mutations had a significantly lower response rate than did NRAS wild-type patients (7.7% vs. 38·1% respectively; odds ratio [OR], 0.14; P = 0.013). 42 Supplementary confirmatory data were subsequently presented in a large (N = 1630) phase III randomized study of first-line chemotherapy with or without cetuximab. 43 The definitive turning point was the publication of the extended RAS analyses data from the PRIME trial comparing FOLFOX with or without panitumumab in first-line mCRC patients. A detrimental effect of the addition of panitumumab to chemotherapy was observed in patients carrying RAS mutations (HR for PFS, 1.31 [P = 0.008, P for interaction <0.002]; HR for OS, 1.21 [P = 0.04, P for interaction = 0.001]). Moving from such results, the use of anti-EFGR was restricted to RAS wild-type patients by regulatory agencies.
After that, the role of the extended RAS mutations' status was evaluated in all recent randomized trials (main results are summarized in Table 1 ) [44] [45] [46] and was also confirmed in a meta-analyses: no PFS or OS benefit was evident with use of anti-EGFR for tumors carrying any RAS mutation (P > 0.05), and results were consistent between different anti-EGFR agents, lines of therapy, and chemotherapy partners. 47 In terms of clinical outcome, the effect of RAS mutations is still a matter of debate. In the metastatic setting, the prognostic effect of such mutations might be underestimated because of the well-known predictive effect. 43, 48 In the adjuvant setting, a negative prognostic effect has been hypothesized 49, 50 and subsequently confirmed in a large pooled analysis from the PETACC8 and N0147 trials, where KRAS exon 2 mutations were identified as independent predictors of shorter time to recurrence (TTR) (HR, 1.60; 95% CI, 1.60-1.83; P < 0.0001) and OS (HR, 1.52; 95% CI, 1.29-1.79; P < 0.0001) among patients with stage III microsatellite stable (MSS) tumors. 51 A recent meta-analysis investigated the impact of KRAS mutation on outcomes in patients undergoing liver resection. KRAS mutation was negatively associated with OS (HR, 2.24; 95% CI, 1.76-2.85) and relapse-free survival (HR, 1.89; 95% CI, 1.54-2.32) in this setting, where the effect of KRAS mutation might be independent to the use of anti-EGFRs. 52 According to all the previous observations, we should acknowledge that RAS evaluation methods become of paramount importance in the management of CRC patients. Genetic tests should be conducted in highly qualified and certified laboratories and as soon as possible after diagnosis of CRC. The American Society of Clinical Oncology (ASCO) recently provided a Provisional Clinical Opinion Update regarding RAS mutational testing of CRC tissue and is developing a new guideline for marker testing in collaboration with the College of American Pathologists, the Association for Molecular Pathology, and the American Society for Clinical Pathology. 53 Among different detection methods, Sanger sequencing is deemed as a standard method for RAS testing but requires at least 10% to 25% of RAS mutant neoplastic 54 ; pyrosequencing has a sensitivity of less than 5%, but sequencing error rate may be approximately 4% to 25%. 55 Next-generation sequencing platforms (I.E. MiSeq [Illumina Sequencing Systems, San Diego, CA, USA]; Ion Torrent [Life Technologies, Carlsbad, CA, USA]) allow for the identification of single-nucleotide changes, insertions, deletions, and even translocations of multiple genes and loci in a single polymerase chain reaction (PCR); sequencing error rates are approximately 1% and usually 1% to 5% of RAS mutant neoplastic cells are needed. Those methodologies are expected to completely replace older methods in the next few years. 56 Detection of RAS mutations through liquid biopsies is the striking news of the last years. Circulating free DNA can be extracted from blood and might allow for detection of tumorspecific genetic aberrations, leading to assessment of the presence of residual disease, recurrence, and primary/acquired resistance. 57 This method allows catching the dynamisms and the heterogeneity of tumors and identifying emerging RAS mutations leading to acquired resistance to anti-EGFRs. KRAS wild-type patients treated with an anti-EGFR develop mutated KRAS clones in blood during EGFR blockade. Interestingly, such mutated clones decline after withdrawal of treatment, leading to a possible regain of drug sensitivity. 58 Droplet digital PCR and beaming techniques represent new tools able to identify such mutations.a [59] [60] [61] [62] These approaches have been applied in research, but at the moment, they are not applicable in routinely clinical practice for RAS testing because their clinical validity is still under evaluation.
BRAF HISTORY
BRAF is an important player in the EGFR-mediated downstream signaling pathway. It is activated by RAS and is able to affect cell growth, proliferation, and differentiation through the activation of MAP kinase pathway, but also able to influence apoptosis (through the regulation of BCL-2), cell migration (through RHO small GTPases), and survival (through the regulation of other pathways such as BCL-2, RHO, and HIPPO). 63 BRAF V600E mutation affects 8% to 10% of mCRC patients. Interestingly, a higher rate of BRAF mutation incidence (21%) was reported in a cohort of prospectively collected unselected mCRC patients with a high rate of poor performance status (39% with performance status 2-4) and advanced age (37% with age >75 years), thus underlining that incidence of BRAF-mutant patients might be underestimated in clinical trials. 64 The story of BRAF mutation started in 2008 when Di Nicolantonio et al. 65 suggested a possible role as markers of resistance to anti-EGFR in a small retrospective series.
Subsequently, BRAF gained a prominent role as a negative prognostic factor in the metastatic setting where BRAF-mutant patients showed a median OS lower than 12 months in multiple series. [66] [67] [68] [69] Specific clinical features such as advanced age, female sex, right sided-primary location, mucinous histology, MSI, a high rate of nodal and peritoneal metastases, 67,70-72 a peculiar gene signature, 73 and a specific carcinogenesis pathway 74 have been also associated with BRAF V600E mutation. Moreover, when liver metastases are radically resected, BRAF mutated tumors often relapse rapidly, because of the occurrence of extrahepatic lesions. 75, 76 In the adjuvant setting, the prognostic role of BRAF mutation is still controversial, because of the strong association with MSI. In the previously reported pooled analyses of PETACC8 and N0147 trials, BRAF mutation emerged as a strong independent negative prognostic factor for TTR (HR, 1.49; 95% CI, 1.19-1.87; P = 0.0005) and OS (HR, 1.72; 95% CI, 1.33-2.22; P < 0.0001) among stage III CRC MSS patients. 51 Recently, the impact of rare mutations of BRAF (codons 594 and 596), occurring in less than 1% of CRCs, was investigated.
Such mutations were associated with rectal primary tumor location, nonmucinous histology, microsatellite stability, and lack of peritoneal spread. Moreover, no negative prognostic impact was observed (BRAF 594 or 596 mutant vs. BRAF V600E median OS, 62.0 vs. 12.6 months; HR, 0.36; 95% CI, 0.20-0.64; P = 0.002). 77 The debate is still open about the predictive effect of lack of response to anti-EGFRs. Confirmatory findings come from the large data set of chemorefractory mCRC patients (N = 733) included in the European Consortium analyses: response rate to cetuximab with or without chemotherapy was 8.3% (2/24) versus 38.0% (124/326) in BRAF mutant versus wild type, respectively (OR, 0.15; 95% CI, 0.02-0.51; P = 0.0012). 42 Conversely, in nonprespecified retrospective analyses of several phase III trials, BRAF V600E mutation failed to provide evidence for utility as predictive biomarkers because of the small number of patients and lack of statistical power. 78, 79 Main results are summarized in Table 2 . Recently, 80, 81 in a meta-analysis of clinical trials evaluating the efficacy of anti-EGFRs, Rowland et al. 80 showed that among patients carrying RAS wild-type BRAF mutant tumors the HR for OS benefit was 0.97 (95% CI, 0.67-1.41) versus 0.81 (95% CI, 0.70-0.95) for RAS wild type BRAF wild type with a negative P for interaction (P = 0.43). In terms of PFS, the HRs were 0.86 (95% CI, 0.61-1.21) and 0.62 (95% CI, 0.50-0.77) in the 2 groups, respectively, with a positive interaction (P = 0.07). 78 On the other side, in a meta-analysis including 9 phase III trials and 1 phase II trial (6 first-line, 2 second-line trials, and 2 trials involving chemorefractory patients), Pietrantonio et al. 81 demonstrated that the addition of anti-EGFR in BRAFmutant patients did not significantly improve PFS (HR, 0.88; 95 CI%, 0.67-1.14; P = 0.33), OS (HR, 0.91; 95% CI, 0.62-1.34; P = 0.63), and overall response rate (ORR) (relative risk, 1.31; 95% CI, 0.83-2.08; P = 0.25) compared with control regimens.
In our opinion, those results show that anti-EGFRs do not demonstrate a clear outcome benefit in BRAF-mutant patients; moreover, those drugs might affect quality of life in terms of toxicity and treatment costs in this group of patients. Such evidence underlines the importance of the identification of tailored treatment options. In the first-line setting, FOLFOXIRI plus bevacizumab represents the most promising treatment option in clinically selected BRAF-mutant patients. 4, 82 Many trials have been conducted in the last few years aiming at the identification of possible effective BRAF inhibitors for mCRC patients. Unfortunately, results are not as exciting as those observed in other diseases such as melanoma; more recently, a huge effort has been made in order to identify more promising combinations of drugs. [83] [84] [85] [86] [87] Other articles in this issue focus on BRAF-directed treatment.
MSI AS PROGNOSTIC, PREDICTIVE, AND THERAPEUTIC TARGET
DNA MSI phenotype is caused by deficient DNA mismatch repair (MMR) as a consequence of germline mutations in MMR genes or, more commonly, epigenetic silencing of the MLH1 gene with frequent mutations in the BRAF oncogene. During DNA synthesis, MMR proteins repair base-pair mismatch errors in tandemly repeated sequences named microsatellites, in order to maintain genomic stability. Deficient MMR results in the production of truncated, nonfunctional protein or loss of a protein, which causes MSI phenotype. Germline mutations in the MMR genes (MLH1, MSH2, MSH6, and PMS2) lead to an autosomal dominant hereditary syndrome named hereditary nonpolyposis CRC or Lynch syndrome. 88, 89 Patients with Lynch syndrome are more likely to present synchronous tumors and at younger ages (between 20 and 30 years) compared with other CRC patients and rarely carry BRAF mutation. 90 Moreover, they show higher risk to develop not only CRC but also endometrial, gastric, ovarian, urinary tract, and small intestine cancers. 91 The MSI phenotype is present in approximately 15% of CRCs; its frequency is higher in stage II (approximately 20%) than in stage III (approximately 12%) and decreases in the metastatic setting (4%). 92 Microsatellite instable tumors share specific clinical and pathologic features, such as right-sided primary location, poor differentiation, mucinous histology, and increased numbers of tumor-infiltrating lymphocytes. 93 Microsatellite instability testing can be performed by means of IHC or PCR-based assay. A panel of microsatellite markers has been validated and recommended as a reference panel for PCR analyses. 94 In terms of prognosis, MSI status has been shown to confer a good outcome in patients with localized disease. Those data derive from retrospective analyses of adjuvant treatment clinical trials or clinical trial population-based studies and meta-analyses. 88, [95] [96] [97] Subgroup analyses of the QUASAR trial, evaluating the efficacy of 5-fluorouracil (5-FU) adjuvant treatment compared with observation in the adjuvant setting showed that recurrence rate in patients with MSI tumors was 11% (25/218), compared with 26% (438/1695) in the MSS cohort (risk ratio, 0.53; 95% CI, 0.40-0.70). 98 A large meta-analysis of pooled data from 31 trials, including 1972 MSI of 12,782 stage I-IV CRC patients, showed an association between MSI and favorable prognosis both in terms of OS (OR, 0.6; 95% CI, 0.53-0.69; P < 0.0001) and disease-free survival (OR, 0.58; 95% CI, 0.47-0.72; P < 0.0001). 99 In the metastatic setting, a recent large pooled analysis of 4 randomized first-line phase III trials (CAIRO, CAIRO2, FOCUS, and COIN) evaluated the impact of MSI and BRAF in terms of outcome. Progressionfree survival and OS were significantly reduced in the MSI cohort, in comparison to the MSS cohort (median PFS, 6.2 vs. 7.6 months, respectively [HR, 1.33; 95% CI, 1.12-1.57; P = 0.001]; median OS, 13.6 vs. 16.8 months, respectively [HR, 1.35; 95% CI, 1.13-1.61; P = 0.001]). The negative prognostic effect of the BRAF mutation was confirmed; no interaction between the 2 markers was demonstrated, thus suggesting that the poor prognostic value of MSI is driven by the BRAF status in this setting. 100 All the available evidence suggests that the prognostic impact of MSI could be stronger in earlier-stage than in advanced-stage tumors. 101, 102 More controversial is the role of MSI as a predictive factor of response to 5-FU-based therapy. 95, 96, 98, [103] [104] [105] [106] The most accepted interpretation of the role of MSI in the adjuvant setting derives from results of the ACCENT database. Such analyses were aimed at the evaluation of the impact of MSI in stages II and III CRC among 17 adjuvant trials comparing surgery versus surgery followed by 5-FU-based therapy. Among patients treated with surgery alone, those with stage II and MSI tumors showed better TTR (5-year TTR, 89% vs. 74%; HR, 0.35; 95% CI, 0.15-0.80; P = 0.013) and OS (5-year OS, 90 vs. 78%; HR, 0.37; 95% CI, 0.17-0.81; P = 0.013) compared with those with MSS; similar results were observed when comparing MSI versus MSS stage III patients (5-year TTR, 60% vs. 47% [HR, 0.79; 95% CI, 0.45-1.39; P = 0.41]; 5-year OS, 59 vs. 54% [HR, 0.84; 95% CI, 0.49-1.43; P = 0.51]). Moreover, in stage III CRC patients, a significant survival benefit for 5-FU monotherapy versus surgery alone was seen not only in patients with MSS tumors (5- year TTR, 64% vs. 47%), but also in patients with MSI tumors (5-year TTR,72% vs. 60%). The authors suggest that chemotherapy is not recommended for patients with stage II and MSI tumors because of their excellent prognosis, whereas stage III patients should receive adjuvant treatment irrespective of MSI status. 107 Recently, MSI gained a prominent role in the metastatic setting because of the discovery of immunotherapy susceptibility. A phase II study evaluated the clinical activity of pembrolizumab, an 108 At the moment, the mechanisms explaining such results are not fully understood; the most validated hypothesis suggests a role for the high mutation rate observed in MSI tumors. Those mutations lead to a high tumor neoantigen rate and higher lymphocyte infiltrate and finally reveal a role of the patient's immune system. 109, 110 Detailed explanations of such mechanisms will be provided elsewhere in this issue.
WHY IS RESEARCH OF BIOMARKERS SO HARD?
Except for the previously mentioned RAS, BRAF, and MSI, at the moment there are no other relevant biomarkers in CRC.
Biomarker validation represents a major issue in translational oncology. Many attempts have been made in order to find adequate biomarkers for antiangiogenic drugs with disappointing results. Among them many pharmacogenetic studies have been conducted aiming at the evaluation of VEGFA single-nucleotide polymorphisms (SNPs) as predictors of bevacizumab's efficacy. [111] [112] [113] Our group carried out a large, retrospective genotyping analysis of 4 SNPs in VEGFA gene −2578 C > A, −1498 C > T (rs833061), 936 C > T, 405 C > G for 218 mCRC patients, 111 treated with FOLFIRI plus bevacizumab and 107 treated with FOLFIRI alone. In the bevacizumab group, patients carrying the VEGF rs833061 T/T genotype showed shorter PFS (HR, 2.13; 95% CI, 1.41-5.10; P = 0.0027), whereas none of the SNPs were associated with outcome in the control group. Because of the positive interaction between VEGFA rs833061 and treatment effect, a possible predictive role for the SNP was suggested. 114 In order to confirm these data, we subsequently conducted a prospective validation study, and 424 patients treated with first-line FOLFIRI plus bevacizumab were enrolled. At the univariate analysis, no differences in PFS according to VEGF rs833061 C/T variants were observed (P = 0.38), so the primary endpoint was unmet, and the predictive effect of VEGF rs833061 C/T SNP was denied. There might be many possible reasons for these negative results. The hypothesis of identifying a single VEGFA SNP as a strong predictor of bevacizumab's efficacy may be too naive, because more and more evidence underlines the importance of tumor heterogeneity, the complexity of bevacizumab mechanism of action, and the assessment of antiangiogenic treatments response. [115] [116] [117] Disappointing results were also derived from the research of predictive factors for anti-EGFR efficacy. Despite many attempts, the predictive effects of PIK3CA mutations and of PTEN loss are still unclear in mCRC receiving anti-EGFRs because of the lack of validation studies.
As exemplified previously for RAS, BRAF, and MSI, prognostic biomarkers might emerge from small retrospective studies but deserve robust multisite validation. Predictive biomarkers require even more extensive data for validation derived from large randomized clinical trials and meta-analysis. Clinical trials are often not adequately powered for biomarker discovery and validation; moreover, statistical correction is needed for provisional data to avoid the risk of false-positive associations, and every effort should be made to have adequate validation sets. From a clinical and methodological perspective, researchers should do their best to avoid false-positive results and look at their data in a rigorous and critical way because their preliminary results would lay the basis for the next step of confirmatory validating trials. [118] [119] [120] Besides statistics, technical issues puzzle biomarker research. In particular, when adopting new technologies such as next-generation sequencing, there is no consensus on sample requirements, and the debate is open on whether archived tumors, fresh tissue biopsy, or a liquid biopsy should be selected for profiling. Moreover, assays adopted to identify biomarkers require rigorous standardization and quality assurance evaluation performed in certified laboratories. 121 With the emergence of more sophisticated gene expression techniques, several groups tried to develop potential molecular classifications of CRC able to simplify biomarker research and disease stratification. Recently, the CRC Subtyping Consortium reanalyzed existing gene expression-based CRC subtyping algorithms and developed a new molecular classification by crosscomparing different subtypes and resolving inconsistencies in number and interpretation of previous series. Key biological features, such as mutation, copy number, methylation, microRNA, and proteomics, as well as correlation with outcome, were described. Four colorectal molecular subgroups (CMSs) were identified: CMS1 (14% of CRC) associated with MSI, hypermutated phenotype, BRAF mutation, immune activation, and worse survival after relapse; CMS2 (37%) with epithelial signature, high number of somatic copy number alterations, marked WNT, and MYC signaling activation; CMS3 (13%) with epithelial signature, evident metabolic dysregulation, and KRAS mutations; and CMS4 (23%) with mesenchymal pattern, prominent transforming growth factor β activation, stromal invasion and angiogenesis, and worse relapse-free survival and OS. 12 This new classification represents a step forward to a better understanding of CRC biology, and a deeper knowledge will be developed in the next feature, thanks to the integration with "omics" data and new treatments. A potential weakness of this classification is the inclusion of stages I to IV CRC patients, thus showing a too simplified and static picture of CRC.
As a matter of a fact, tumor heterogeneity is another significant concern in the biomarker research field. More and more evidence describes genetic and epigenetic differences between tumors of the same type in different patients, between cancer cells within a tumor, and in the same tumor during disease progression. Such modifications might lead to different treatment responses and possible mechanisms of acquired resistance to therapies. In this panorama, liquid biopsies and dynamic biomarkers might be a valuable tool able to catch tumor heterogeneity and dynamism across subsequent lines of treatment. 115, 122, 123 
POSSIBLE WAYS OUT
The increasing complexity of CRC biology knowledge, the more advanced sequencing techniques, and the emergence of new drugs targeting genetic aberration lead researchers to develop new tools to able to increase the quality of biospecimen collection and the integration of biomarkers in early-phase clinical trials.
In the past few years, many efforts have been made in order to improve tissue collection. In clinical trials, the collection of biospecimens or their derivatives (such as extracted RNA, DNA, or proteins) is becoming mandatory because it can help identify molecular markers of sensitivity or resistance to new drugs. Moreover, the concept of biobanking specimens emerged as a new tool. It refers to the collection of clinical biopsy-type specimens (liquid biopsies or biopsies of recurrent primary or metastatic tumors) collected from patients at distinct time points and in prespecified time points of cancer progression and treatment, which are subsequently made ready for analysis through new high-throughput technologies. Large-scale international initiatives, such as the International Cancer Genome Consortium, tried to standardize the collection and storage of biospecimens to limit preanalytical variability and to ensure sufficient quality for analysis of samples. 124 Recently, a platform named SPECTAcolor (Screening Patients for Efficient Clinical Trial Access in advanced Colorectal Cancer) has been built up among European country with the aim of prospectively biobanking fully annotated tumor samples and analyzing possible biomarkers from patients with mCRC and finally developing personalized treatments based on the results of the tissue sampling analysis. This approach allows the improvement of sample collection, data analyses, and biomarker research quality and the enrolment of patient from all over Europe to new molecularly driven trials with a huge economic convenience.
Facing with a so big amount of genomics data, many efforts have been made in order to develop more efficient and effective cancer drug development strategies. Clinical trials with different designs are used in very early drug development phases. Patient selection according to tumor genomic profile may be adopted in dose escalation and/or cohort expansion stages of phase I trials when biomarker have strong scientific background and preclinical data.
Umbrella trials involve the testing of different drugs targeting different mutations either in a single cancer subtype or in a variety of cancer subtypes. These studies typically utilize an individualized treatment plan formulated after analysis of the molecular profile of each patient's tumor. A prespecified series of treatment is used with a refined molecularly guided decision tree or algorithm. Among umbrella trials, the Cancer Research UK has developed FOCUS 4; in this study, mCRC patients after the first 16 weeks of first-line chemotherapy are randomized to receive treatment according to results of biomarker panel assessment or placebo. Primary objectives are PFS and OS. 125 Basket trials are genotype-focused designs where a single drug on a specific mutation or mutations is tested in different cancer types. Each cohort is analyzed separately but in the same clinical trial. If the treatment under study demonstrates a signal of efficacy in a particular cohort, the cohort can be expanded to enroll more patients with the identified cancer type, whereas cohorts that do not demonstrate efficacy can be closed. This approach is advantageous when the mutation is rare because it allows flexibility for a combination of multiple, independent, small studies within a single trial. The intent of basket trials can be either exploratory or for registration. Among basket trials, Novartis developed the SIGNATURE study, the enrolment started in 2013, and preliminary results were presented at the last ASCO Congress. Primary objective of the study is clinical benefit (SD or better for ≥16 weeks). Patients receive a specific drug according to the molecular profile. The most common tumor types involved are CRC and non-small cell lung cancer. The most frequent genetic alterations among treated patients were RAS mutation (68%), PIK3CA mutation (55%), and PTEN loss (41%). Preliminary activity was observed in various tumors. 126 "Hybrid" trials represent a mix of umbrella and basket trial design frameworks; a single protocol might include either multiple umbrella subtrials (same histology, different molecular aberrations) or multiple basket subtrials (same molecular aberrations, different histologies). The National Cancer Institute (NCI) developed 2 examples of such trial, the NCI-MPACT (Molecular Profiling-Based Assignment of Cancer Therapy) and NCI-MATCH (Molecular Analysis for Therapy Choice). The first one identifies genetic alteration and randomizes patients to receive a treatment that targets that alteration or a different nontarget cancer treatment. Primary endpoints are ORR and PFS. Current targeted drugs studied in MPACT include ABT-888 (poly ADP ribose polymerase inhibitor) with temozolomid, AZD1775 (MK-1775) (Wee1 inhibitor) with carboplatin, and trametinib (MEK inhibitor). 127 The second one analyzes patients' tumors to determine whether they contain actionable mutations and assigns treatment based on the abnormality. It is a phase II study, and primary endpoint is ORR. Enrollment started in August 2015, and target accrual is 3000 patients. 128 
CONCLUSIONS
The deeper understanding of CRC biology and the large amount of data obtained from molecular profiling and "omics" techniques point out colon cancer as a heterogeneous disease with no driver mutations.
Translational research is focusing on the early identification of biomarkers during clinical development of new anticancer drugs. Such an approach should inform the design and conduct of early-phase clinical trials and allow consistency between populations in early-phase and phase III clinical trials.
Providing a benchmark to the international community based on a set of common principles for the integration of biomarkers into trials is important to facilitate exchange of data, promote quality, and accelerate research while respecting local approaches and legislation. Recently, a risk management approach was developed by an NCI, National Cancer Research Institute, and European Organisation for Research and Treatment of Cancer working group in order to effectively integrate biomarkers in clinical trials. 129 Finally, it is important to understand that molecular profiles are dynamic and might change under treatment pressure; thanks to the development of liquid biopsies, we are now able to molecularly monitor our patients in real time and to identify molecular mechanism of escape informing us of possible novel treatment options. 130 
